FDA panel backs anemia drugs for kidney disease

Oct 18, 2010

(AP) -- Federal health advisers say patients with failing kidneys should continue taking a group of widely used anemia drugs, despite a recent study showing they can increase the risk of stroke.

A panel of experts voted 15-1 to maintain the drugs' approval for patients with chronic who are not yet sick enough to receive dialysis. The FDA is not required to follow the group's advice, though it often does.

The panel is now scheduled to discuss altering recommended doses of the drugs to increase their safety.

The FDA is reviewing the three blood-boosting medications from Amgen Inc. after a study published last year that showed kidney disease patients taking them were twice as likely to experience compared with those taking a dummy treatment.

Explore further: US appeals court upholds delay in Alzheimer's drug swap

0 shares

Related Stories

Study finds stroke risk from anemia drug Aranesp

Oct 31, 2009

(AP) -- A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick ...

FDA questions safety of Glaxo kidney cancer drug

Oct 01, 2009

(AP) -- Federal regulators said Thursday an experimental kidney cancer drug from GlaxoSmithKline may cause liver problems, potentially outweighing its ability to slow the disease.

Abbott withdraws diet pill in US, Canada

Oct 08, 2010

(AP) -- Abbott Laboratories said Friday it will withdraw its diet pill Meridia in the U.S. and Canada, almost a year after studies showed the drug increases the risk of heart attack and stroke in patients with a history ...

FDA confirms benefits of Crestor in more patients

Dec 11, 2009

(AP) -- Federal scientists say AstraZeneca's cholesterol pill Crestor lowers the risk of heart attack, death and stroke in patients without a history of heart disease, though some safety concerns remain.

Recommended for you

US appeals court upholds delay in Alzheimer's drug swap

May 22, 2015

A federal appeals court has rejected a drug manufacturer's appeal and affirmed a judge's order that Actavis PLC keep distributing its widely used Alzheimer's medication until after its patent expires this summer.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.